When cancer spreads from its original location to the liver, treatment decisions become more complex—but hope remains alive through a combination of proven therapies and cutting-edge research that aims to control disease, ease symptoms, and extend life with dignity.

Understanding Treatment Goals When Cancer Reaches the Liver

When cancer travels from another part of the body to settle in the liver, medical teams face a unique challenge. The liver, being one of the body’s largest and most vital organs, filters more than 250 gallons of blood every single day, which unfortunately makes it a common destination for wandering cancer cells^[6]. The treatment approach depends heavily on where the cancer started, how many tumors have formed in the liver, whether the disease has spread beyond the liver, and the patient’s overall health and personal wishes^[1][10].

For some patients, particularly those with cancer that originated in the colon or rectum, treatment may still aim for cure if the spread is limited to the liver and can be completely removed^[12]. However, for many others, the goal shifts toward controlling the cancer’s growth, managing symptoms, and maintaining the best possible quality of life for as long as possible. This is known as palliative treatment, which focuses on comfort and function rather than cure^[10].

Medical societies have established guidelines for treating liver metastases, and doctors follow these recommendations while tailoring treatment to each individual’s situation. At the same time, researchers around the world are testing promising new therapies in clinical trials, offering options that may become tomorrow’s standard treatments^[9]. Understanding your options—both established and experimental—empowers you to participate actively in decisions about your care.

Standard Treatment Approaches

Surgical Removal of Liver Metastases

Surgery remains the only treatment proven to potentially cure patients with liver metastases, particularly those whose cancer started in the colon or rectum. Five-year survival rates after complete surgical removal of all visible liver tumors can reach up to 40 percent^[12]. However, only about 25 percent of patients with colorectal liver metastases are candidates for this major operation^[12].

Surgeons consider several factors before recommending liver surgery. The primary cancer must be under control, the metastases should be confined to the liver without spread to other organs, and enough healthy liver tissue must remain after removal to support the body’s essential functions^[10][19]. The liver has a remarkable ability to regenerate, which makes partial removal feasible in selected cases.

The surgery itself, called liver resection, is complex and can take several hours. Patients typically spend at least 24 hours in intensive care following the procedure and may remain hospitalized for 10 to 21 days^[10][19]. Full recovery takes about six weeks. Some patients receive chemotherapy before surgery to shrink tumors or after surgery to reduce the risk of cancer returning.

In certain cases, doctors prepare the liver for surgery using a technique called portal vein embolization. This involves blocking a branch of the main vein feeding the liver, which encourages the healthy portion to grow larger before surgery. This helps ensure enough liver tissue remains after tumor removal and reduces the risk of liver failure^[10][19]. Sometimes surgeons perform the removal in two stages, taking out part of the liver in a first operation, then removing more a week or so later—a strategy called staged liver resection.

Systemic Chemotherapy

Chemotherapy uses powerful drugs to kill cancer cells throughout the body. The specific drugs chosen depend entirely on where the cancer originally started—colorectal, breast, lung, and pancreatic cancers each respond to different medication combinations^[10][19]. When liver metastases accompany cancer in other parts of the body, systemic chemotherapy becomes the most appropriate choice^[12].

Doctors typically begin with first-line chemotherapy, which represents the most effective known treatment for that particular cancer type. If the disease progresses despite initial treatment, second-line chemotherapy using different drugs may be offered^[10][19]. The duration of treatment varies widely, from several months to ongoing therapy, depending on how well the cancer responds and how tolerable the side effects are.

Common side effects of chemotherapy include fatigue, nausea and vomiting, hair loss, increased infection risk, and changes in appetite. Not everyone experiences all side effects, and many can be managed with supportive medications. Your medical team monitors you closely throughout treatment and adjusts doses or switches drugs if needed to maintain your quality of life.

Hepatic Artery Infusion Chemotherapy

For patients whose liver metastases cannot be surgically removed but whose cancer remains confined to the liver, doctors may recommend delivering chemotherapy directly into the liver’s blood supply. This approach, called hepatic artery infusion, places a thin tube into the main artery feeding the liver. High concentrations of chemotherapy drugs flow directly to the tumors while minimizing exposure to the rest of the body^[10][19].

This targeted delivery method allows doctors to use stronger doses than would be safe with standard chemotherapy, potentially improving effectiveness while limiting side effects. Patients usually stay in the hospital overnight or longer for these treatments. However, this approach is not suitable for everyone—it works best when cancer is limited to the liver without spread elsewhere^[10][19].

Ablation Therapies

Ablation refers to techniques that destroy tumors using extreme temperatures or energy. Several ablation methods exist for treating liver metastases that cannot be surgically removed. These procedures directly destroy cancer cells without requiring major surgery^[6][9].

Radiofrequency ablation uses extreme heat generated by electrical energy to kill cancer cells. A probe is inserted through the skin into the tumor, guided by imaging such as ultrasound or CT scans. The procedure works best for smaller tumors—typically those under 3 centimeters—and can be repeated if needed^[12].

Cryotherapy takes the opposite approach, using extreme cold to freeze and destroy tumor tissue^[12]. Like radiofrequency ablation, it’s most effective for smaller, localized tumors when more extensive treatment isn’t possible.

Newer ablation techniques include histotripsy, which uses high-energy ultrasound waves to mechanically destroy tumor cells^[6]. These procedures typically cause fewer side effects than major surgery and allow faster recovery, though they’re not appropriate for all tumor sizes or locations within the liver.

Embolization Procedures

Liver tumors depend heavily on blood supply from the hepatic artery, while normal liver tissue receives most of its blood from the portal vein. Doctors exploit this difference using techniques that block the artery feeding the tumor, essentially starving it of oxygen and nutrients.

Transarterial chemoembolization, or TACE, combines two approaches: delivering chemotherapy directly into the tumor’s blood supply, then blocking that artery with tiny particles. The doctor threads a thin tube through an artery in the leg or arm up to the liver’s main artery. Chemotherapy is injected first, followed by an embolic agent—a substance that blocks the blood vessel. This cuts off the tumor’s blood supply while trapping the chemotherapy inside the tumor for maximum effect^[10][19].

The blocked blood flow damages cancer cells by depriving them of oxygen, while the concentrated chemotherapy attacks from within. Meanwhile, healthy liver tissue continues receiving blood through the portal vein. This procedure can be repeated and is particularly useful when tumors are too large or numerous for surgery.

Radiation Therapy

Traditional radiation therapy uses high-energy beams to kill cancer cells. However, the liver is sensitive to radiation, making it challenging to deliver enough radiation to destroy tumors without damaging healthy tissue. This has changed with the development of stereotactic body radiotherapy, or SBRT^[14].

SBRT delivers very precise, high-dose radiation to tumors while sparing nearby healthy liver tissue. This computer-assisted, noninvasive therapy works best for smaller liver tumors when other treatments aren’t possible or recommended. The precision comes from sophisticated imaging and treatment planning that maps the exact tumor location and tracks its movement with breathing^[14].

Treatment Being Tested in Clinical Trials

Targeted Therapy Drugs

Unlike traditional chemotherapy that attacks all rapidly dividing cells, targeted therapy drugs zero in on specific proteins or genetic changes that drive cancer growth. These medications may cause fewer side effects because they spare more healthy cells, though they’re sometimes combined with traditional chemotherapy for greater effectiveness^[14].

Several targeted drugs have shown promise in clinical trials for liver metastases. Sorafenib and regorafenib are multikinase inhibitors that block proteins signaling tumors to grow or form new blood vessels feeding the tumor^[14]. These drugs are particularly studied in patients with advanced liver cancer or when surgery isn’t immediately possible because tumors are too large or positioned too close to critical blood vessels.

For colorectal cancer that has spread to the liver, bevacizumab works by decreasing the tumor’s blood supply—essentially cutting off its lifeline. Another drug, cetuximab, can slow tumor growth by interfering with growth signals. Both are being tested in various combinations with chemotherapy^[14].

Clinical trials typically progress through phases. Phase I trials primarily test safety and determine proper dosing in small groups of patients. Phase II trials evaluate whether the treatment shows effectiveness against the cancer in larger groups. Phase III trials compare the new treatment against current standard treatment in even larger patient populations to definitively establish whether it offers improvement^[9].

Immunotherapy

Immunotherapy represents one of the most exciting developments in cancer treatment. Rather than directly attacking cancer cells, these treatments harness the body’s own immune system to recognize and fight the disease. Cancer cells often evade the immune system through various mechanisms—immunotherapy aims to remove those shields.

Nivolumab is an immunotherapy drug called an anti-PD1 inhibitor that has shown promise in clinical trials for advanced liver cancer. By blocking the PD-1 protein, it prevents cancer cells from hiding from immune cells, essentially accelerating the immune system’s response to shrink tumors or slow their growth^[14]. This drug recently received approval from regulatory authorities for treating people with advanced liver cancer, based on research showing meaningful benefits.

Ongoing clinical trials continue evaluating nivolumab both alone and in combination with other immunotherapy drugs or treatments. Researchers are particularly interested in understanding which patients respond best to immunotherapy and how to combine it with other approaches for maximum benefit^[14].

Immunotherapy can cause unique side effects different from traditional chemotherapy. Because it activates the immune system, it may trigger inflammatory reactions affecting various organs. These side effects are generally manageable but require close monitoring by experienced medical teams.

Innovative Locoregional Approaches

Researchers continuously develop new ways to deliver treatment directly to liver tumors while minimizing effects on the rest of the body. These locoregional therapies have evolved as major treatment options for unresectable metastatic disease, with applications ranging from attempting cure for small tumors to controlling larger ones or providing symptom relief in advanced disease^[9].

One newer radiation technique under investigation is selective internal radiation therapy. This approach delivers radioactive particles directly into the liver’s blood vessels, where they lodge in small capillaries feeding the tumor and emit localized radiation over time. This allows higher radiation doses to reach the tumor compared to external beam radiation while protecting healthy liver tissue^[12].

Clinical trials testing these innovative approaches occur at specialized cancer centers in various countries including the United States, Europe, and increasingly in other regions. Patient eligibility depends on many factors including the primary cancer type, extent of liver involvement, overall health status, and previous treatments received. Your oncologist can help determine whether any clinical trials might be appropriate for your specific situation.

Most Common Treatment Methods

• Surgery
  • Liver resection removes portions of the liver containing metastases and can potentially cure selected patients when cancer is confined to the liver^[12]
  • Portal vein embolization prepares the liver for surgery by encouraging healthy tissue to grow before tumor removal^[10][19]
  • Staged liver resection removes liver tissue in two separate operations spaced about a week apart^[10][19]
• Chemotherapy
  • Systemic chemotherapy uses drugs that travel throughout the body to kill cancer cells, with specific medications chosen based on the primary cancer type^[10][19]
  • Hepatic artery infusion delivers high concentrations of chemotherapy directly into the liver’s blood supply^[10][19]
  • Transarterial chemoembolization combines direct chemotherapy delivery with blocking the tumor’s blood supply^[10][19]
• Ablation
  • Radiofrequency ablation uses extreme heat to destroy tumor tissue, most effective for smaller metastases^[12]
  • Cryotherapy freezes tumor tissue to kill cancer cells^[12]
  • Histotripsy uses high-energy ultrasound waves to mechanically destroy tumors^[6]
• Radiation Therapy
  • Stereotactic body radiotherapy delivers precise, high-dose radiation to tumors while protecting healthy liver tissue^[14]
  • Selective internal radiation therapy delivers radioactive particles directly into liver blood vessels feeding tumors^[12]
• Targeted Therapy
  • Sorafenib and regorafenib block proteins that signal tumors to grow or form blood vessels^[14]
  • Bevacizumab decreases blood supply to tumors, particularly for colorectal cancer liver metastases^[14]
  • Cetuximab interferes with growth signals to slow tumor growth in colorectal cancer^[14]
• Immunotherapy
  • Nivolumab blocks the PD-1 protein to help the immune system recognize and attack cancer cells^[14]
  • Other immunotherapy drugs continue being tested in clinical trials, both alone and in combinations^[14]